|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. CONCLUSIONOver the past two decades much has been learned about the virus that causes AIDS and the natural history of the disease. Much research that guided success in treating HIV has been done in the developed world. The virus’s pathogenic mechanisms are still being investigated. Research continues to develop improved and additional therapeutics to combat HIV and AIDS. As the epidemic knows no borders, it will be important that research on antiretroviral therapies and their advantages and disadvantage continue to be conducted around the globe. REFERENCESBartlett J. 2004. Antiretroviral treatment. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. 3rd Edition. Philadelphia, PA: Lippincott, Williams & Wilkins. Pp. 1028–1038. Bennett JE, Dolin R, Mandell GL. 2000. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 5th Edition. Philadelphia, PA: Churchill Livingstone. Centers for Disease Control and Prevention. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Review Weekly 41(51):961–962. Clavel F, Hance A. 2004. HIV drug resistance. New England Journal of Medicine 350(10): 1023–1035. Deeks S. 2002. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362(9400): 2002–2011. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D’Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:2003 recommendations of an international AIDS society-USA panel. Clinical Infectious Diseases 37:113–128. Kilby JM, Eron JJ. 2003. Mechanisms of disease: Novel therapies based on mechanisms of HIV-1 cell entry. New England Journal of Medicine 348(22). Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV Infection in North and South America. New England Journal of Medicine 348(22):2175–2185. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. 2003. Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348(22): 2228–2238. MSF (Médecins sans Frontières). 2004. Two Pills a Day Saving Lives: Fixed-Dose Combinations (FDCs) of Antiretroviral Drugs. Geneva: Médecins sans Frontières. Petrello M, Brenner B, Loemba H, Wainberg MA. 2002. HIV drug resistance implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resistance Updates 4:339–346. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro M, Bozzette S. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1–7.
|
|
|||||||||||||||
